$NVDL .004 True Value .02+, Yahoo Target $1.00!
Post# of 72741
Posted On: 09/05/2013 11:51:18 PM
[b]$NVDL .004 True Value .02+, Yahoo Target $1.00![/b]
http://www.novadel.com/index.html
[color=red]52 Week .03+, 3 Year .25+ With 0 Liabilty and Huge News Expect a Nice Return.
[/color]
[b]SHARE STRUCTURE
91 Million Float,[/b]
130 Million O/S
39 Million Held Inside
[b]
2 HUGE PATENTED FDA APPROVED PRODUCTS
[/b]
NitroMist® or ZolpiMist™ intellectual property or licenses
http://www.novadel.com/pipeline/nitromist.htm
http://www.novadel.com/pipeline/zolpimist.htm
[b]NovaDel has two marketed products that have been approved by the FDA: NitroMist® for the treatment of angina, and ZolpiMist™ for the treatment of insomnia.[/b]
[color=blue]During the twelve months of 2012, the Company earned royalties from the license of NitroMist and ZolpiMist in the amount of $471,000. The Company also received $200,000 from the sale of NitroMist rights outside the US, Canada and Mexico. Also included in revenue is the recognition of previously received payments under various license agreements[/color]
[b]HUGE NEWS RELEASED AUGUST 13/2013[/b]
Selling Majority of Assets for $400,000 plus 50,000,000 Shares of SUDA LTD. with an Option for 10,000,000 more at .05 Per Share
http://finance.yahoo.com/news/novadel-announc...00171.html
[b]
That's a $2,400,000 - $3,400,000 Deal which our TOP RATE CEO plans to eliminate Liabilites.[/b]
[b]Steven B. Ratoff[/b]
President & Chief Executive Officer
[b]Senior VP and CFO of the Pharmaceutical Group at Bristol-Myers Squibb[/b]. Mr. Ratoff brings extensive credentials to the Company from his distinguished career in the pharmaceutical and consumer goods industries.
FULL[b] IN DEPTH LEADERSHIP[/b]
http://www.novadel.com/about/leadership.htm
http://www.novadel.com/index.html
[color=red]52 Week .03+, 3 Year .25+ With 0 Liabilty and Huge News Expect a Nice Return.
[/color]
[b]SHARE STRUCTURE
91 Million Float,[/b]
130 Million O/S
39 Million Held Inside
[b]
2 HUGE PATENTED FDA APPROVED PRODUCTS
[/b]
NitroMist® or ZolpiMist™ intellectual property or licenses
http://www.novadel.com/pipeline/nitromist.htm
http://www.novadel.com/pipeline/zolpimist.htm
[b]NovaDel has two marketed products that have been approved by the FDA: NitroMist® for the treatment of angina, and ZolpiMist™ for the treatment of insomnia.[/b]
[color=blue]During the twelve months of 2012, the Company earned royalties from the license of NitroMist and ZolpiMist in the amount of $471,000. The Company also received $200,000 from the sale of NitroMist rights outside the US, Canada and Mexico. Also included in revenue is the recognition of previously received payments under various license agreements[/color]
[b]HUGE NEWS RELEASED AUGUST 13/2013[/b]
Selling Majority of Assets for $400,000 plus 50,000,000 Shares of SUDA LTD. with an Option for 10,000,000 more at .05 Per Share
http://finance.yahoo.com/news/novadel-announc...00171.html
[b]
That's a $2,400,000 - $3,400,000 Deal which our TOP RATE CEO plans to eliminate Liabilites.[/b]
[b]Steven B. Ratoff[/b]
President & Chief Executive Officer
[b]Senior VP and CFO of the Pharmaceutical Group at Bristol-Myers Squibb[/b]. Mr. Ratoff brings extensive credentials to the Company from his distinguished career in the pharmaceutical and consumer goods industries.
FULL[b] IN DEPTH LEADERSHIP[/b]
http://www.novadel.com/about/leadership.htm
(0)
(0)